Skip to main content

Table 5 Characteristics of patients (n = 110) with clinical relevant improvement vs. no improvement in the transition from dialysis to transplantation in the domains “symptoms” and “effect of kidney disease”

From: Is HRQOL in dialysis associated with patient survival or graft function after kidney transplantation?

  Improvement in symptoms No improvement in symptoms p value Improvement in effect of kidney disease No improvement in effect of kidney disease p value
Agea 48 ± 13 57 ± 16 <0.01 50 ± 15 57 ± 14 0.04
Female, % 32 35 0.74 27 47 0.05
Comorbidityb 4 (2–6) 5 (4–6) 0.02 4 (3–6) 5 (3–6) 0.53
Time in dialysisa 1.9 (1.0–2.5) 1.7 (1.3–3.3) 0.36 1.7 (1.1–2.7) 2.2 (1.4–3.7) 0.02
eGFRc 59 ± 21 56 ± 20 0.40 57 ± 19 61 ± 22 0.30
Living donor,% 26 32 0.47 32 19 0.27
  1. Data presented as mean ± standard deviation or median with interquartile range as appropriate
  2. aAt time of renal transplantation, in years; bCharlson Comorbidity Index in dialysis; cEstimated glomerular filtration rate in ml/min/1.732, at time of HRQOL measurement after transplantation